This article is available online at http://www.jlr.org ated by its receptor, the tyrosine kinase proto-oncogene c-fms (also known as Csf1r ). Interleukin-34 (IL-34) has been recently identifi ed as another ligand for CSF1-R; however, its role in atherosclerosis has yet to be elucidated. Infl ammatory disorders that display elevated levels of CSF-1 include arthritis, obesity, and atherosclerosis ( 7 ). The potential involvement of CSF-1 in atherosclerosis was fi rst suggested by the observation that CSF-1 is induced in endothelial cells by treatment with oxidized lipids ( 8 ) and is expressed at high levels in atherosclerotic lesions ( 8, 9 ). Subsequently, it was shown that osteopetrotic ( op/op ) mice carrying a Csf1 null mutation, either on an apolipoprotein E (apoE) Ϫ / Ϫ or a low density lipoprotein receptor null
x 129T2/SvEMsJ background was collected. Bone marrow from this mixed background was used because we were unable to obtain Csf1 Ϫ / Ϫ mice on an inbred B6 background. The 129 strain was chosen because its haplotype is compatible with B6 mice. Eight-week-old recipients were lethally irradiated and injected via the tail vein with 10 7 bone marrow cells as previously described ( 17 ) . Five weeks after transplantation the animals were placed on a Western-type diet for 12 weeks. Leukocyte DNA was isolated to confi rm the presence of the Csf1 null allele or the presence of the Sry gene by PCR as appropriate.
Quantitation of infl ammatory gene expression
Total RNA was isolated using an RNEASY kit (Qiagen, Valencia, CA). cDNA was synthesized with iScript cDNA Synthesis Kit (Biorad, Hercules, CA). Quantitative PCR was performed on an Applied Biosystems 7700 unit using Platinum SYBR Green qPCR Supermix UDG (Invitrogen, Carlsbad, CA). Samples were analyzed in duplicate and normalized to ␤ (2)-microglobulin (B2M) expression. B2M, a component of the MHC I complex, is an ubiquitous and stably expressed factor.
Statistical tests
Data were expressed as mean +/ Ϫ SEM. Statistical analyses were performed using the nonparametric Mann Whitney test (Statview, SAS Institute, Cary, NC) for all comparisons. Lesion data were displayed as a box plot and whiskers, the central line representing the overall median, the bottom of the box representing the median of the fi rst quartile of the data set, and the top of the box representing the median third quartile of the data set. Open circles represent outliers beyond the 9th and 91st percentiles.
RESULTS

Dose-dependent effects of an CSF-1 defi ciency in a defi ned genetic background
Interaction of Csf1 mutation and genetic background. To study the mechanism by which a CSF-1 defi ciency contributes to atherosclerosis, we sought to place the Csf1 null mutation on an inbred genetic background. For this, we repeatedly crossed the mutation, originally on a mixed C57BL/6JxC3HeB/FeJ background, to inbred C57BL/6J mice. We felt this was important as C3H mice are highly resistant to atherosclerosis and nearly a dozen major loci contribute to the differences in susceptibility between C57BL/6 and C3H mice on an apoE null background ( 18 ) . After 10 generations of backcrossing, we intercrossed heterozygous mice. Over 120 mice from this cross were genotyped, which resulted in a ratio that was greatly skewed from the expected 1:2:1 ratio. Approximately equal numbers of +/+ and +/ Ϫ mice were observed; only 2 mice were of the Ϫ / Ϫ genotype. Thus, both the heterozygous and homozygous null genotypes were associated with dramatically reduced viability. Even on a mixed genetic background, Csf1 Ϫ / Ϫ mice had reduced size and weight at birth as well as osteopetrosis and a lack of tooth eruption ( 19, 20 ) . We chose to use primarily heterozygous mice in this study. While both male and female mice were examined, we present here our analysis on female mice. The male data (supplementary data at www.jlr.org) yielded similar conclusions, although there were some signifi cant differences.
appear to be likely candidates as CSF-1 is expressed by both cell types and expression is dramatically induced in EC by oxidized LDL and by proinfl ammatory molecules, such as bacterial lipopolysaccaride ( 8 ) . CSF-1 has previously been shown by immunohistochemistry to be abundantly produced in human and rabbit atherosclerotic lesions but not in the normal vessel wall ( 9, 13 ) . Because CSF-1 defi ciency has such a dramatic impact on atherosclerosis, we have been interested in the possibility that pharmacologic inhibition of CSF-1 signaling could be a useful therapeutic intervention. We have examined the effects of a CSF-1 receptor kinase inhibitor (GW2580) ( 14 ) on infl ammation and atherosclerosis.
MATERIALS AND METHODS
Animal husbandry
Csf1 heterozygous mice on a C57BL/6JxC3HeB/FeJ mixed genetic background were purchased from the Jackson Laboratory (Bar Harbor, ME) and backcrossed for ten generations to C57BL/6J mice, at which point the mice were crossed to LDLR Ϫ / Ϫ on the same background. At approximately 10 weeks of age the mice were placed on a Western-type diet (TD 88137, Teklad, Madison, WI) for 13 weeks before sacrifi ce. The Animal Research Committee of the University of California at Los Angeles approved all animal work.
CSF-1 receptor kinase inhibitor synthesis
GW2580 was synthesized as previously described ( 14 ) . The compound (or carrier) was administered orally at 80 mg/kg twice a day for 8 weeks to 8-week-old low density lipoprotein receptor (LDLR) Ϫ / Ϫ female mice.
Quantitation of atherosclerosis, plaque composition, and immunohistochemistry
Atherosclerotic lesions in the proximal aorta and aortic root were measured as previously reported ( 15 ) . The ascending and descending aorta was pinned out en face and stained with Oil red O as in Tangirala et al. ( 16 ) . Lesion surface area and total aortic surface area were measured using Image Pro Plus (Media Cybernetics). Frozen sections from the proximal aorta were stained for plaque composition by a Movat pentachrome stain, macrophages (rat anti-mouse MOMA-2, BD Biosciences, San Jose, CA) and proliferating cells (rabbit-anti mouse Ki67, Abcam).
Peritoneal macrophage and monocyte migration assays
Mice were injected intraperitoneally with 1 ml of 3% brewer's yeast thioglycolate four days before sacrifi ce. Cells were isolated by fl ushing the peritoneal cavity with cold PBS. Red blood cells were lysed and peritoneal cells were counted. Monocyte migration was determined in vitro using a human artery wall coculture model ( 17 ) .
Apoptosis
The ApopTag Fluorescein In Situ Apoptosis Detection Kit (Millipore, Billerica, MA), utilizing a terminal deoxynucleotidyl transferase (TdT)-based technique, was used to quantitate apoptosis within atherosclerotic lesions of the aortic root. aortic root atherosclerosis ( Fig. 2 ) , plasma CSF-1 levels, or circulating monocyte counts (supplementary Table II Table III ). In this experiment, the male Csf1 +/ Ϫ mice showed a trend toward decreased lesion size that did not reach statistical significance (data not shown). We conclude that the levels of artery wall-derived CSF-1 is most important in mediating the effect of CSF-1 on atherosclerosis and that an absence of macrophage-derived CSF-1 has little or no impact on atherosclerosis.
Mechanisms contributing to lesion development
Aortic infl ammatory gene expression. Csf1
mice demonstrated a 7-fold decrease in aortic Csf1 expression and a 3-fold decrease in SRA expression ( Fig. 3 ) . One would expect a 2-fold decrease in Csf1 expression when examining heterozygous mice, but as macrophages express this cytokine themselves, the large decrease we observed in aortic Csf1 expression probably refl ects the decreased macrophage content ( Fig. 1 ) and atherosclerosis ( Fig. 2 ) of Csf1
Atherosclerotic lesions. Examination of the aortic root by immunostaining clearly revealed decreased macrophage content and a reduced the rate of plaque formation in female Csf1 -defi cient mice. Intimal lesion macrophage content decreased by 50% ( Fig. 1 Table I ). Csf1
showed a 40% decrease in proximal aorta atherosclerosis ( Fig. 2 ). This decrease was not observed in the thoracic and abdominal aorta of female Csf1 +/ Ϫ mice, as measured by en face staining of lipids (supplementary Fig. I-A ) . We observed no differences in plasma lipids, circulating monocytes, overall number of cells per unit of lesion area (data not shown), number of proliferating cells (supplementary text and Fig. II-A ) , fi brous caps, or prominent lipid cores per aortic root section ( Table 1 , supplementary Tables I, II) .
CSF-1 derived from monocyte/macrophages does not infl uence lesion development.
As discussed above, monocytes/macrophages are capable of abundant CSF-1 expression. To test whether monocyte/macrophage-derived CSF-1 contributed to lesion development, we conducted bone marrow transplantation experiments. We transplanted bone marrow from Csf1 +/+ and Csf1 Ϫ / Ϫ donors into lethally irradiated LDLR Ϫ / Ϫ recipients and placed the animals on a 12-week Western diet. No signifi cant differences were detected in Circulating monocytes. We did not detect a difference in circulating levels of CD115+ (CSF-1 receptor expressing) monocytes ( Table 1 , 
CSF-1 infl uences macrophage apoptosis in lesions.
The decreased macrophage content we observed in atherosclerotic lesions from Csf1 -defi cient mice raised the possibility of an effect on macrophage apoptosis. We quantitated apoptosis in lesions by measuring DNA fragmentation using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining. The number of apoptotic nuclei varied from 0 to 22 per section in each group and overlapped almost exclusively with lesion areas positive for the be upregulated by Csf1 ( 21 ) , but in this case, decreased SRA expression is attributable to decreased macrophage content of the lesion. No signifi cant changes in CD36, KC, or MCP-1 expression were detected (data not shown); however, those cDNAs were detected at levels so low in the control arterial samples that detecting further decreases in expression in Csf1 -defi cient mice would be highly unlikely.
Effect of CSF-1 on monocyte migration. We examined the possible role of CSF-1 in monocyte recruitment using an in vitro monocyte migration assay ( 17 ) and an in vivo peritoneal macrophage recruitment assay (supplementary Fig.  III-A ) . Addition of a CSF-1 neutralizing antibody to an in vitro assay consisting of cocultures of endothelial and smooth muscle cells signifi cantly decreased monocyte migration in response to oxidized lipids, whereas control antiserum had no effect. Consistent with this, peritoneal cavity monocyte recruitment in response to thioglycolate exhibited a signifi cant decrease in Csf1 +/ Ϫ LDLR Ϫ / Ϫ animals. These experiments support the idea that CSF-1 has a chemotactic role in the artery wall and that the haploinsuffi ciency of Csf1 in Csf1 +/ Ϫ animals can alter monocyte migration in the context of atherosclerosis. (*** P < 0.001, ** P < 0.01). CSF-1, colony stimulating factor-1; wt, wild-type at the Csf1 locus; het, heterozygous at the Csf1 locus; ko, null at the Csf1 locus. potential for the compound to be effective in inhibiting atherogenesis in vivo. The inhibitor was dosed orally twice a day at 80 mg/kg into LDLR Ϫ / Ϫ female mice for 8 weeks.
This dose was chosen based on previous work ( 14 ) indicating that free drug levels in the plasma would remain within the IC 50 range for suppression of monocyte proliferation while maintaining 100-fold selectivity for kinase inhibition. Lesion size was reduced ‫ف‬ 40% ( P < 0.05), and relative plasma PON activity was elevated 28% ( P < 0.05) ( Fig. 5 ).
Using the same coculture model mentioned previously, we observed that HDL from the group treated with GW2580 retained the protective capacity to inhibit LDL-mediated monocyte migration while HDL from control mice lost this ability (supplementary Fig. IV-C ) . No changes in plasma lipid levels were detected (supplementary Fig. V ) . GW250 was added to cultured peritoneal macrophages to determine if phosphorylation of Akt, an event known to occur downstream of CSF-1R signaling and an important factor in cell survival/proliferation, had been altered. Thioglycolate-elicited peritoneal macrophages isolated from C57BL6/J mice were cultured for one week in regular media, media supplemented with 10 ng/ml of recombinant CSF-1 (as a positive control), or with 1 M of the CSF1-R kinase inhibitor GW250. This concentration of inhibitor should selectively inhibit all endogenous signaling only through this receptor. Western blots of cell lysates were probed for phospho-Akt and total Akt levels. It was observed that phospho-Akt levels decreased 89% using GW2580 after normalization to total Akt levels while increasing 155% upon addition of recombinant CSF-1 (supplementary Fig. VII) . macrophage marker MOMA-2 ( Fig. 4A -B , supplementary Fig. VI-A, B ) . Female Csf1 +/ Ϫ lesion sections did not show an increase in apoptotic cell content relative to lesion. However, after normalizing for the number of apoptotic cells by the percentage of MOMA-2-positive lesion area, we observed approximately 2-fold increased apoptosis in Csf1
LDLR
Ϫ / Ϫ mouse lesions ( P < 0.05) ( Fig. 4D ).
Additional studies were conducted to determine cell survival using mouse bone marrow derived macrophages from either Csf1 +/+ or Csf1 +/ Ϫ mice. Cells were cultured for six days in regular media or media supplemented with recombinant CSF-1. We observed that both groups of cells treated with CSF-1 continued to proliferate over the six days and displayed a spread out morphology typifi ed by various cellular projections. In contrast to that, cells starved of CSF-1 displayed a much more rounded morphology and appeared not to proliferate at all. Their numbers declined precipitously after six days in culture compared with cells not starved of CSF-1 (data not shown).
Pharmacologic inhibition of CSF-1 signaling decreases atherosclerosis
On the basis of the clear dose-dependent inhibitory effect of a CSF-1 reduction on lesion formation, we tested the effect of blocking CSF-1 signaling by inhibiting the intrinsic kinase activity of the CSF-1 receptor with a highly selective, orally bioavailable, small-molecule kinase inhibitor GW2580 ( 14 ) . We initially detected the ability of this compound to inhibit LDL-or MCP-1-mediated monocyte migration in a dose-dependent manner using an artery wall coculture model (supplementary Fig. IV-A ) . This suggested there was small change in adiposity (from 19.1% to 22.5%, P < 0.05), no differences were observed. We also found no changes in food intake or blood monocyte counts in mice treated with the inhibitor (data not shown).
DISCUSSION Our studies with Csf1
+/ Ϫ LDLR Ϫ / Ϫ mice showed that the effect of CSF-1 on atherosclerosis was dependent on decreased artery wall-derived CSF-1, rather than monocyte/ macrophage-derived CSF-1. It resulted in decreased lesional macrophage content and increased lesional macrophage apoptosis. Also, our studies with a specifi c CSF-1 receptor kinase inhibitor (GW2580) suggest that pharmacologic inhibition of CSF-1 signaling may be a promising therapy for atherosclerosis. Studies of Csf1 -defi cient mice on ApoE Ϫ / Ϫ ( 12 ) and LDLR Ϫ / Ϫ backgrounds ( 11 ) have revealed dramatic decreases in aortic atherosclerosis. These studies were conducted using mice on a mixed background ( 12 ) where the Csf1 Ϫ / Ϫ mice had signifi cant decreases in circulating monocytes and were generally unhealthy, with striking osteopetrosis. In the current study we used Csf1
animals backcrossed for ten generations to the C57BL/6J background to demonstrate an approximate 2-fold decrease in female aortic root lesions. Although not reaching signifi cance, aortic root lesions in male Csf1 +/ Ϫ mice trended strongly toward a similar decrease in lesion size while showing a signifi cant decrease in lesions when measured by an en face approach. Sex-specifi c and regionspecifi c differences in lesion susceptibility are frequently To better understand the anti-infl ammatory effects of GW2580, infl ammatory gene expression was determined in the atherosclerotic aorta and the liver. As in the Csf1 +/ Ϫ mouse lesions, 70%-80% reductions were observed in the tissue macrophage-specifi c marker F4/80 ( P < 0.01), the pan-monocyte/macrophage marker CSF1-R (the CSF-1 receptor) ( P < 0.001), and the scavenger receptor SRA ( P < 0.01) ( Fig. 6A ) . Matrix metallopeptidase-9 (MMP-9) expression, an enzyme secreted by macrophages that can degrade the matrix and fi brous cap causing lesion destabilization, declined ‫ف‬ 90% ( P < 0.001). ICAM-1 and E-Selectin, both factors expressed by the endothelium early in plaque formation and involved in the fi rm adhesion of monocytes to the artery wall prior to their entry, showed 70%-80% reduced expression in the CSF-1R inhibitor-treated group. Urokinase plasminogen activator receptor (uPAR), a direct target of CSF-1 signaling, was signifi cantly downregulated as well ( Fig. 6B ) . In contrast to the aorta, hepatic CSF-1R expression tripled ( P < 0.05) while F4/80 levels declined 50% ( Fig. 6C ) , suggesting that while the overall macrophage content of liver decreased, there appears to be a feedback loop linking the inhibition of CSF-1 signaling with increased expression of CSF-1 receptor in the remaining tissue macrophages. The expression of other key infl ammatory mediators and markers of infl ammatory macrophages, such as IL-6 and IL-1 ␤ , decreased by 50%-80% in the liver. Hepatic CSF-1 expression itself declined 50% ( P < 0.05).
Genetic defi ciencies of CSF-1 or its receptor are known to increase bone density and decreasing adiposity. We studied adiposity using NMR and bone density using DEXA in response to GW2580 treatment. Except for a Fig. 4 . Quantitation of apoptosis in the aortic root of CSF-1-defi cient mice. Aortic root plaque cryosections were stained for apoptotic cells (green) using a TUNEL assay and counterstained for macrophages with a MOMA-2 antibody in red. Nuclei were stained blue with DAPI. Apoptotic nuclei (yellow areas indicated with arrows) were detected within Csf1 +/+ LDLR Ϫ / Ϫ lesions (A) and Csf1
. Apoptotic cells were within areas of macrophage infi ltration (black circles). Quantitation of lesional apoptosis (C-F). (* P < 0.05, magnifi cation 400×). CSF-1, colony stimulating factor-1; I, intima; LDLR, low density lipoprotein receptor; M, media; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling; wt, wild-type at the Csf1 locus; het, heterozygous at the Csf1 locus. fi ciency on atherosclerosis, using bone marrow transplantations. These experiments suggested that artery wall-derived CSF-1 is the primary source of circulating CSF-1 and is the key source of CSF-1 as it relates to atherosclerosis. This could be due to differences in the half-life, stability, activity, and cell signaling properties among the three major isoforms of CSF-1: cell surface, secreted glycoprotein, and secreted proteoglycans. For example, cell-surface CSF-1 has a longer half-life than the secreted forms but only works observed in mouse atherosclerotic lesion studies. We believe the data demonstrates that decreasing CSF-1 levels resulted in decreased atherosclerosis but that the interplay of complex factors outlined above are responsible for the variations observed between males and females.
A large body of work has addressed the role of CSF-1 in a variety of macrophage functions ( 22 ) . We sought to distinguish the effects of a macrophage-specifi c CSF-1 defi ciency on atherosclerosis, as opposed to an artery wall-specifi c de- it could be due to the decreased plaque size in CSF-1-defi cient mice. As previously reported, we also observed that a lack of CSF-1 supplementation severely impaired cultured bone marrow macrophage survival. On the basis of our work and previous studies, we explored the potential of therapeutic inhibition of CSF-1 action for treatment of atherosclerosis. We tested GW2580, a compound that has been demonstrated to have at least 100-fold greater inhibitory capacity for the CSF-1R kinase when tested against an array of related kinases, such as the PDGF and VEGF receptor tyrosine kinases ( 14 ) . GW2580 was administered at a dose required to maintain free-plasma levels (unbound to albumin) of the inhibitor in the range of 100 nM, near the IC 50 for inhibiting monocyte growth, with the assumption that the albumin-associated compound has very limited bioactivity. At the dose used, GW2580 suppressed atherogenesis to about the same extent observed in CSF-1 heterozygous mice ( Fig. 2A ) . Although other kinase inhibitors, including imatinib ( 31 ) and SU11248 ( 32 ) , can inhibit CSF-1 receptor kinase activity, they also inhibit several other kinases and are not selective for this single target.
We also observed that GW2580 could suppress monocyte migration in an artery wall coculture model and that HDL from treated LDLR Ϫ / Ϫ mice retained the ability to block LDL-mediated monocyte migration while HDL from control LDLR Ϫ / Ϫ mice lost this protective capacity (supplementary Fig. IV-C ) . This phenomenon presumably occurs as a result of the elevated infl ammatory state engendered by a high-fat diet in atherosclerotic mice ( 17 ) and is associated with the displacement of PON1 and platelet-activating factor acetyl hydrolase (PAF-AH) enzymes from HDL particles. Both PON1 and PAF-AH have the ability to inactivate oxidized lipids. The ability to suppress lesion formation, improve the anti-oxidant capacity of HDL, and reduce the overall infl ammatory state while not altering lipid levels, body composition, or bone density (data not shown) suggests that, in principal, pharmacologic inhibition of CSF-1 signaling can selectively suppress infl ammation and lesion formation, properties that are desirable when considering the use of a compound in human coronary artery disease (CAD). By analyzing a panel of infl ammatory gene expression profi les derived from the aorta and liver of mice treated with GW2580, we are able to generate an improved understanding of the molecular changes associated the decreased lesion formation. It is known that the early steps of atherosclerosis involve oxidized lipid-mediated expression of monocyte adhesion molecules and that defi ciencies in VCAM-1 and ICAM-1 have signifi cant effects on lesion size ( 33 ) . Further development of atherosclerosis occurs via the conversion of migrating monocytes into activated infl ammatory macrophages that are characterized by the production of cytokines, such as IL-1 ␤ , IL-6, and others. The rupture of an unstable plaque represents another manifestation of activated macrophages in light of the evidence that several matrix metalloproteinases are found in lesions. Expression of the activated form of MMP-9 resulted in the disruption of plaques within the innominate artery of ApoE Ϫ / Ϫ mice ( 34 ).
GW2580 treatment substantially decreased the expression of all these genes as well as general markers of mature when in direct contact with the macrophage. In an infl ammatory kidney model, ( 23 ) the secreted proteoglycan form of CSF-1 enhances macrophage accumulation beyond what is observed with cell-surface CSF-1. Therefore, differences between the isoforms of CSF-1 produced by macrophages and the artery wall cells could have signifi cant effects on plaque formation and macrophage function within the artery wall or even prior to entering the vessel. Infusion of a neutralizing antibody to the CSF-1 receptor in ApoE Ϫ / Ϫ mice resulted in signifi cantly decreased atherosclerotic lesions despite no signifi cant differences in circulating monocytes ( 24 ) . That report and our work indicate that reducing signaling through the CSF-1 receptor (primarily expressed on mononuclear phagocytes) by decreasing artery wall-derived CSF-1 or blocking CSF-1 receptor ligand binding results in decreased atherosclerosis.
One of the functions of CSF-1 is its ability to act directly as a monocyte chemotactic factor ( 5, 25 ) . We showed a specifi c role for CSF-1 in monocyte migration in the context of a model of the artery wall by neutralizing oxidized LDLstimulated endothelial and smooth muscle cell-derived CSF-1. In this model, MCP-1 induced in response to oxidized LDL is thought to be primarily responsible for monocyte migration into the artery wall. Our results show that CSF-1 also has a signifi cant role in this process, and it is possible that CSF-1 and MCP-1 signaling pathways interact in the monocyte or that CSF-1 itself can induce endothelial cell-derived MCP-1 ( 26 ) . We also showed that Csf1 +/ Ϫ LDLR Ϫ / Ϫ animals have signifi cantly fewer thioglycolate-elicited peritoneal cells, a population of cells rich in macrophages, which suggests an in vivo role for CSF-1 in macrophage migration. This in vivo role of CSF-1 was substantiated in other studies where a single treatment of GW2580 blocked the migration of intravenously injected GFP-expressing macrophages into subcutaneous mouse 3LL lung cancer tumors 24 h post injection ( 27 ) . The peripheral leukocyte surface markers CD115 (the CSF-1 receptor) has been used to defi ne populations of monocytes. We observed no change the overall frequency of CD115+ monocytes ( CSF-1 does not alone strongly regulate these aspects of monocyte development. The data also suggest that the decreased atherosclerosis observed in CSF-1 defi cient mice is not attributable to fewer circulating monocytes. CSF-1 signaling through its receptor, the kinase c-fms, likely mediates macrophage survival via activation of phosphatidylinositol 3-kinase and Akt kinase activity ( 28, 29 ) . CSF-1R inhibition in peritoneal macrophages with GW250 reduced endogenous phospho-Akt levels 89% (supplementary Fig. VII) . Oxidized LDL is known to be toxic to macrophages ( 30 ) and other vascular cells, and we hypothesized that CSF-1-defi cient macrophages within lesions would be more prone to undergo apoptosis. Indeed, we observed about a 2-fold increase in the number of TUNEL-positive cells that coincided with MOMA-2-positive regions of atherosclerotic lesions in Csf1 +/ Ϫ LDLR Ϫ / Ϫ mice ( Fig. 4 ) . Despite this, the exact nature of the causal relationship between decreased CSF-1 expression and apoptosis is unclear as Supplemental Material can be found at:
